444152 MDM2 Antagonist IV, Nutlin-3a - CAS 675576-98-4 - Calbiochem

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₃₀H₃₀Cl₂N₄O₄ 675576-98-4

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
444152-5MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 5 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable and highly potent active enantiomer of Nutlin-3 (Cat. No. 444143) that binds to the p53-binding pocket and blocks the interaction of p53 and MDM2 (IC50 = 90 nM). Exhibits over 150-fold greater affinity for MDM2 than its less active enantiomer, Nutlin-3b. Induces p53 mediated apoptosis by both transcription-dependent and independent mechanisms. Shown to greatly potentiate the cytotoxic effects of chemotherapeutic agents and reduce tumor burden in vivo. Also shown to overcome ATM-mediated resistance to fludarabine in chronic lymphocyte leukemia. Cells treated with Nutlin-3a permanently lose their ability to proliferate and enter into a pattern of permanent senescence. Mouse embryonic fibroblasts with p53+/+MEFs show significantly reduced reprogramming capabilities following Nutlin-3a treatment.
      Catalogue Number444152
      Brand Family Calbiochem®
      Synonyms(-)-4-(4,5-bis-(4-Chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazole-1-carbonyl)piperazine-2-one
      References
      ReferencesOhnstad, H.O., et al. 2011. BMC Cancer 11, 211.
      Shen, H. and Maki, C.G., 2010. J. Biol. Chem. 285, 23105.
      Kawamura, T., et al. 2009. Nature 460, 1140.
      Kojima, K., et al. 2006. Blood 108, 993.
      Laurie, N.A., et al. 2006. Nature 444, 61.
      Tovar, C., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 1888.
      Vassilev, L.T. 2006. Trends Mol Med. 13, 23.
      Thompson, T., et al. 2004. J. Biol. Chem. 279, 53015.
      Vassilev, L.T., et al. 2004. Science 303, 844.
      Product Information
      CAS number675576-98-4
      FormWhite powder
      Hill FormulaC₃₀H₃₀Cl₂N₄O₄
      Chemical formulaC₃₀H₃₀Cl₂N₄O₄
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      MDM2 Antagonist IV, Nutlin-3a - CAS 675576-98-4 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      MDM2 Antagonist IV, Nutlin-3a - CAS 675576-98-4 - Calbiochem Certificates of Analysis

      TitleLot Number
      444152

      References

      Reference overview
      Ohnstad, H.O., et al. 2011. BMC Cancer 11, 211.
      Shen, H. and Maki, C.G., 2010. J. Biol. Chem. 285, 23105.
      Kawamura, T., et al. 2009. Nature 460, 1140.
      Kojima, K., et al. 2006. Blood 108, 993.
      Laurie, N.A., et al. 2006. Nature 444, 61.
      Tovar, C., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 1888.
      Vassilev, L.T. 2006. Trends Mol Med. 13, 23.
      Thompson, T., et al. 2004. J. Biol. Chem. 279, 53015.
      Vassilev, L.T., et al. 2004. Science 303, 844.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision10-August-2012 JSW
      Synonyms(-)-4-(4,5-bis-(4-Chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazole-1-carbonyl)piperazine-2-one
      DescriptionA cell-permeable and highly potent active enantiomer of Nutlin-3 (Cat. No. 444143) that binds to the p53-binding pocket and blocks the interaction of p53 and MDM2 (IC50 = 90 nM). Exhibits over 150-fold greater affinity for MDM2 than its less active enantiomer, Nutlin-3b. Induces p53 mediated apoptosis by both transcription-dependent and independent mechanisms. Shown to greatly potentiate the cytotoxic effects of chemotherapeutic agents and reduce tumor burden in vivo. Also shown to overcome ATM-mediated resistance to fludarabine in chronic lymphocyte leukemia. Cells treated with Nutlin-3a permanently lose their ability to proliferate and enter into a pattern of permanent senescence. Mouse embryonic fibroblasts with p53+/+MEFs show significantly reduced reprogramming capabilities following Nutlin-3a treatment.
      FormWhite powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number675576-98-4
      Chemical formulaC₃₀H₃₀Cl₂N₄O₄
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage -20°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesOhnstad, H.O., et al. 2011. BMC Cancer 11, 211.
      Shen, H. and Maki, C.G., 2010. J. Biol. Chem. 285, 23105.
      Kawamura, T., et al. 2009. Nature 460, 1140.
      Kojima, K., et al. 2006. Blood 108, 993.
      Laurie, N.A., et al. 2006. Nature 444, 61.
      Tovar, C., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 1888.
      Vassilev, L.T. 2006. Trends Mol Med. 13, 23.
      Thompson, T., et al. 2004. J. Biol. Chem. 279, 53015.
      Vassilev, L.T., et al. 2004. Science 303, 844.